References
- Frohman EM, Racke MK, Raine CS. Multiple sclerosis: the plaque and its pathogenesis. N. Engl. J. Med.354, 942–955 (2006).
- Warnke C, Menge T, Hartung HP et al. Natalizumab and progressive multifocal leukoencephalopathy: what are the causal factors and can it be avoided? Arch. Neurol.67, 923–930 (2010).
- Sandrock AW, Hotermans C, Richman S et al. Risk of natalizumab-associated progressive multifocal leukoencephalopathy. Int. J. MS Care13(Suppl. 3), 53–54 (2011).
- Miravalle A, Jensen R, Kinkel R. Immune reconstitution syndrome in multiple sclerosis patients following cessation of natalizumab therapy. Arch. Neurol.68(2), 186–191 (2011).
- Stüve O, Marra CM, Bar-Or A et al. Altered CD4+/CD8+ T cells ratios in cerebrospinal fluid of natalizumab-treated patients with multiple sclerosis. Arch. Neurol.63, 1383–1387 (2006).
- Stüve O, Marra CM, Jerome KR et al. Immune surveillance in multiple sclerosis patients treated with natalizumab. Ann. Neurol.59, 743–747 (2006).
- Gorelik L, Reid C, Testa M et al. Progressive multifocal leukoencephalopathy (PML) development is associated with mutations in JC virus capsid protein vp1 that change its receptor specificity. J. Infect. Dis.204(1), 103–114 (2011).
- Miller DH, Khan OA, Sheremata WA et al. A controlled trial of natalizumab for relapsing multiple sclerosis. N. Engl. J. Med.348, 15–23 (2003).
- Stüve O, Cravens PD, Frohman EM et al. Immunological and clinical status 14 months after cessation of natalizumab therapy. Neurology72(5), 396–401 (2009).
- Vellinga MM, Castelijns JA, Barkhof F et al. Postwithdrawal rebound increase in T2 lesional activity in natalizumab-treated MS patients. Neurology70, 1150–1151 (2008).
- West TW, Cree BAC. Natalizumab dosage suspension: are we helping or hurting? Ann. Neurol.68, 395–399 (2010).
- O’Connor PW, Goodman A, Kappos L et al. Disease activity return during natalizumab treatment interruption in patients with multiple sclerosis. Neurology76(22), 1858–1865 (2011).
- Khatri BO, Man S, Giovannoni G et al. Effect of plasma exchange in accelerating natalizumab clearance and restoring leukocyte function. Neurology72, 402–409 (2009).
- del Pilar Martin M, Cravens PD, Winger R et al. Decrease in the numbers of dendritic cells and CD4+ T cells in cerebral perivascular spaces due to natalizumab. Arch. Neurol.65, 1596–1603 (2008).
- Gorelik L, Lerner M, Bixler S et al. Anti-JC virus antibodies: implications for PML risk stratification. Ann. Neurol.68, 295–303 (2010).
- Polman CH, O’Connor P, Havrdova E et al. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N. Engl. J. Med.354, 899–910 (2006).
- Rudick RA, Stuart WH, Calabresi PA et al. Natalizumab plus interferon β-1 for relapsing multiple sclerosis. N. Engl. J. Med.354, 911–923 (2006).
- Goodman AD, Rossman HS, Bar-Or A et al. GLANCE: results of a Phase 2, randomized, doubleblind, placebo-controlled study. Neurology72, 806–812 (2009).
Websites
- Standard response letter; Biogen Idec. July 2011 https://medinfo.biogenidec.com
- Treatment Interruption of Natalizumab (RESTORE). ClinicalTrials.gov identifier: NCT01071083 http://clinicaltrials.gov/ct2/show/NCT01071083